[Changes of Willebrand factor level in blood plasma of cancer patients and its role in hemostatic disturbances].
Plasma concentrations of von Willebrand (WF) factor were measured in patients with different tumors and healthy donors. The study has shown the level of WF in cancer patients to be significantly higher than in healthy donors. Hypercoaggulation was identified by laboratory analysis in breast cancer patients only while patients with other malignant tumors revealed the signs of chronic DIC syndrome. Chemotherapy provoked further increase in WF level in the plasma of patients with acute myeloleukemia and breast cancer. The importance of plasma WF assay for diagnosis and prediction of thromboembolic complications in cancer patients is discussed.